Debt (Details Narrative) |
3 Months Ended | 6 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb. 01, 2027 |
Jun. 08, 2026
USD ($)
|
Jun. 03, 2026
USD ($)
Integer
$ / shares
|
May 01, 2026
USD ($)
shares
|
Feb. 01, 2026 |
Sep. 09, 2025
USD ($)
$ / shares
shares
|
Jul. 30, 2025
USD ($)
Integer
$ / shares
|
Jul. 28, 2025
USD ($)
$ / shares
|
May 13, 2025 |
May 30, 2024
$ / shares
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
|
Aug. 01, 2025
USD ($)
|
|
| Short-Term Debt [Line Items] | ||||||||||||||||
| Accrue interest payable rate | 12.70% | 12.30% | ||||||||||||||
| Convertible Debt, Noncurrent | $ 753,235,000 | $ 753,235,000 | $ 195,324,000 | |||||||||||||
| Discount amount | 8,401,000 | |||||||||||||||
| Loss on debt extinguishment | 11,477,000 | 11,477,000 | ||||||||||||||
| Interest expense | 3,500,000 | 3,200,000 | 7,900,000 | 6,400,000 | ||||||||||||
| Debt issuance costs and discount amortization | 400,000 | $ 300,000 | 900,000 | $ 600,000 | ||||||||||||
| Fair value of note payable | 160,200,000 | |||||||||||||||
| Future payments | $ 0 | $ 0 | ||||||||||||||
| 2031 Notes [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Debt instrument principal amount | $ 50,000,000 | |||||||||||||||
| 2032 Notes [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Debt instrument principal amount | $ 50,000,000 | |||||||||||||||
| 2032 Note Underwriting Agreement [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Repayment of debt | $ 137,400,000 | |||||||||||||||
| 2032 Note Underwriting Agreement [Member] | June 2026 Convertible Notes Offering [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Debt instrument principal amount | 575,000,000 | $ 500,000,000 | ||||||||||||||
| Accrue interest payable rate | 0.80% | 0.80% | ||||||||||||||
| Conversion rate | 8.0302 | |||||||||||||||
| Principal amount | $ 1,000 | |||||||||||||||
| Conversion price | $ / shares | $ 124.53 | |||||||||||||||
| Redemption description | The 2032 Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company’s option at any time, and from time to time, on a redemption date on or after August 6, 2029, and on or before the 31st scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the 2032 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding 2032 Notes unless at least $50.0 million aggregate principal amount of the 2032 Notes are outstanding and not called for redemption as of the time the Company sends the related redemption notice. In addition, calling any 2032 Note for redemption will constitute a Make-Whole Fundamental Change with respect to that 2032 Note, in which case the conversion rate applicable to the conversion of that 2032 Note will be increased in certain circumstances if it is converted after it is called for redemption. | |||||||||||||||
| Percentage of stock price | 130.00% | |||||||||||||||
| Trading days | Integer | 20 | |||||||||||||||
| Consecutive trading days | Integer | 30 | |||||||||||||||
| Convertible Debt, Noncurrent | $ 557,400,000 | $ 557,400,000 | ||||||||||||||
| Fair value of the Notes | 655,600,000 | 655,600,000 | ||||||||||||||
| Discount amount | $ 17,800,000 | |||||||||||||||
| Interest expense | 300,000 | 300,000 | ||||||||||||||
| Amortization of issuance costs | $ 200,000 | $ 200,000 | ||||||||||||||
| 2032 Note Underwriting Agreement [Member] | June 2026 Convertible Notes Offering [Member] | Forecast [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Accrue interest payable rate | 0.25% | |||||||||||||||
| 2032 Note Underwriting Agreement [Member] | June 2026 Convertible Notes Offering [Member] | Over-Allotment Option [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Debt instrument principal amount | 75,000,000 | |||||||||||||||
| Net proceeds from offering | $ 557,200,000 | |||||||||||||||
| 2031 Note Underwriting Agreement [Member] | July 2025 Convertible Notes Offering [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Debt instrument principal amount | $ 175,000,000 | $ 201,300,000 | ||||||||||||||
| Accrue interest payable rate | 2.75% | 3.30% | 3.30% | |||||||||||||
| Conversion rate | 19.4932 | |||||||||||||||
| Principal amount | $ 1,000 | |||||||||||||||
| Conversion price | $ / shares | $ 51.3 | |||||||||||||||
| Redemption description | The 2031 Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company’s option at any time, and from time to time, on a redemption date on or after August 6, 2029, and on or before the 51st scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the 2031 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding 2031 Notes unless at least $50.0 million aggregate principal amount of the 2031 Notes are outstanding and not called for redemption as of the time the Company sends the related redemption notice. In addition, calling any 2031 Note for redemption will constitute a Make-Whole Fundamental Change with respect to that 2031 Note, in which case the conversion rate applicable to the conversion of that 2031 Note will be increased in certain circumstances if it is converted after it is called for redemption. | |||||||||||||||
| Trading days | Integer | 20 | |||||||||||||||
| Consecutive trading days | Integer | 30 | |||||||||||||||
| First Amendment description | beneficially own in excess of 4.99% of the number of shares of the Company’s common stock outstanding immediately prior to, and immediately after giving effect to, the conversion of all or any portion of the 2031 Notes; provided, that such 4.99% beneficial ownership can be increased or decreased at the discretion of the noteholder; provided further, that such limitation in no event can exceed 19.99%. | |||||||||||||||
| Convertible Debt, Noncurrent | $ 195,800,000 | $ 195,800,000 | 195,300,000 | |||||||||||||
| Fair value of the Notes | 422,200,000 | 422,200,000 | $ 436,500,000 | |||||||||||||
| Discount amount | $ 6,400,000 | |||||||||||||||
| Interest expense | 1,600,000 | 3,300,000 | ||||||||||||||
| Discount amount | $ 200,000 | $ 500,000 | ||||||||||||||
| 2031 Note Underwriting Agreement [Member] | July 2025 Convertible Notes Offering [Member] | Over-Allotment Option [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Debt instrument principal amount | 26,300,000 | |||||||||||||||
| Net proceeds from offering | $ 194,900,000 | |||||||||||||||
| Third Amendment to Amended and Restated Loan and Security Agreement [Member] | Term D Loan [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Debt Instrument, Fee Amount | $ 2,800,000 | |||||||||||||||
| Third Amendment to Amended and Restated Loan and Security Agreement [Member] | Term D Loan [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Warrants measurement inputs | 4.1 | |||||||||||||||
| Third Amendment to Amended and Restated Loan and Security Agreement [Member] | Term D Loan [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Warrants measurement inputs | 74.4 | |||||||||||||||
| Third Amendment to Amended and Restated Loan and Security Agreement [Member] | Term D Loan [Member] | Measurement Input, Expected Term [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Warrant expected life | 10 years | |||||||||||||||
| Third Amendment to Amended and Restated Loan and Security Agreement [Member] | Term D Loan [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Warrants measurement inputs | 0 | |||||||||||||||
| Second Amendment To Amended And Restated Loan And Security Agreement [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Debt instrument principal amount | $ 180,000,000 | |||||||||||||||
| Converted shares | shares | 343,802 | |||||||||||||||
| Principal amount | $ 3,438,029 | |||||||||||||||
| Amendment fee payable | $ 100,000 | |||||||||||||||
| Maturity date | May 09, 2026 | |||||||||||||||
| Conversion percentage | 20.00% | |||||||||||||||
| Common stock price per share | $ / shares | $ 10 | |||||||||||||||
| Amount of indebtedness eligible to incur under Term D Loan | $ 30,000,000 | |||||||||||||||
| Loan Agreement [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| First Amendment description | (i) pay Oxford an amendment fee of less than $0.1 million on the effective date of the First Amendment, (ii) extend to March 9, 2026 the expiration date of Innovatus’ right to convert up to 20% of the outstanding principal of the Term A Loan into shares of the Company’s common stock at a price per share of $10.00, (iii) extend the expiration date of the Term D Draw Period to the earlier of (x) August 31, 2025 and (y) the occurrence of an Event of Default (as defined in the A&R Loan Agreement), (iv) update the liquidity covenant to increase the Minimum Liquidity Percentage (as defined in the First Amendment) to 50% if the Company had failed to achieve the Term D Milestone prior to June 1, 2025, and to decrease the Minimum Liquidity Percentage back to 30% if the Company had subsequently achieved the Term D Milestone prior to the end of the Term D Draw Period, and (v) release Innovatus and the Lenders from any and all claims arising out of or related to the A&R Loan Agreement, the First Amendment and related documentation. | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Discount amount | 7,300,000 | |||||||||||||||
| Loss on debt extinguishment | $ 11,500,000 | |||||||||||||||
| Debt instrument interest rate description | the Company was entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions had been met. The Term Loans bore interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined in the A&R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest was payable in-kind by adding an amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May 31, 2027. | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Disbursement loan amount | $ 1,400,000 | |||||||||||||||
| Contingent loan | 120,000,000 | |||||||||||||||
| Amendment fee payable | $ 100,000 | |||||||||||||||
| Final fee percentage | 4.50% | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Warrant [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Warrants exercise price per share | $ / shares | $ 14.84 | |||||||||||||||
| Warrants issued | shares | 50,537 | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term D Loan [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Disbursement loan amount | $ 30,000,000 | |||||||||||||||
| Net proceeds from loan | $ 27,700,000 | |||||||||||||||
| Debt final fee percentage | 4.50% | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term E Loan [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Contingent loan | $ 50,000,000 | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term E Two Loan [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Contingent loan | 100,000,000 | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term F Loan [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Contingent loan | 40,000,000 | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term F Two Loan [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Contingent loan | 45,000,000 | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term G Loan [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Contingent loan | $ 150,000,000 | |||||||||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term A Loan [Member] | ||||||||||||||||
| Short-Term Debt [Line Items] | ||||||||||||||||
| Conversion percentage | 20.00% | |||||||||||||||
| Common stock price per share | $ / shares | $ 10 | |||||||||||||||